Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma. Leupin N, Zinzani PL, Morschhauser F, Dalle S, et al. Cancer 2021 Nov 2. doi: 10.1002/cncr.34005.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Leupin N, Zinzani PL, Morschhauser F, Dalle S, et al. Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma. Cancer 2021 Nov 2. doi: 10.1002/cncr.34005.
PMID: 34726773